SH5 Stock Overview Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sotera Health Company Competitors Price History & Performance
Summary of share price highs, lows and changes for Sotera Health Historical stock prices Current Share Price US$12.70 52 Week High US$15.90 52 Week Low US$9.90 Beta 1.92 1 Month Change -2.31% 3 Month Change -11.81% 1 Year Change -8.63% 3 Year Change -31.30% 5 Year Change n/a Change since IPO -45.42%
Recent News & Updates
Sotera Health Company to Report Fiscal Year 2024 Results on Feb 27, 2025 Jan 14
Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director Jan 07 Firstlight Management Urges Sotera Health to Launch a Sale Process Dec 19
Investor sentiment deteriorates as stock falls 15% Nov 20
Third quarter 2024 earnings released: EPS: US$0.06 (vs US$0.049 loss in 3Q 2023) Nov 06
Sotera Health Company to Report Q3, 2024 Results on Nov 05, 2024 Oct 23 See more updates
Sotera Health Company to Report Fiscal Year 2024 Results on Feb 27, 2025 Jan 14
Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director Jan 07 Firstlight Management Urges Sotera Health to Launch a Sale Process Dec 19
Investor sentiment deteriorates as stock falls 15% Nov 20
Third quarter 2024 earnings released: EPS: US$0.06 (vs US$0.049 loss in 3Q 2023) Nov 06
Sotera Health Company to Report Q3, 2024 Results on Nov 05, 2024 Oct 23 Sotera Health Company has completed a Follow-on Equity Offering in the amount of $375.75 million. Sep 06
Sotera Health Company has filed a Follow-on Equity Offering. Sep 05
Second quarter 2024 earnings released: EPS: US$0.031 (vs US$0.083 in 2Q 2023) Aug 06
Sotera Health Company Reaffirms Earnings Guidance for the 2024 Aug 05
Sotera Health Appoints Christopher Simon to the Board of Directors Aug 01
Sotera Health Company to Report Q2, 2024 Results on Aug 05, 2024 Jul 23 Sotera Health Company Reports Impairment of Long-Lived Assets for the Three Months Ended March 31, 2024
First quarter 2024 earnings released: EPS: US$0.022 (vs US$0.01 in 1Q 2023) May 02 Sotera Health Company to Report Q1, 2024 Results on May 02, 2024
Investor sentiment deteriorates as stock falls 16% Mar 22
Investor sentiment deteriorates as stock falls 16% Mar 06 Sotera Health Company has completed a Follow-on Equity Offering in the amount of $368.75 million. Mar 01
Sotera Health Company Provides Revenue Guidance for the Full-Year 2024 Sotera Health Company has filed a Follow-on Equity Offering. Feb 28
Full year 2023 earnings released: EPS: US$0.18 (vs US$0.83 loss in FY 2022) Feb 28
Sotera Health Company to Report Q4, 2023 Results on Feb 27, 2024 Feb 16
Sotera Health Company Provides Preliminary Revenue Guidance for the Year 2023 Jan 10
Sotera Health Appoints Karen Flynn to Board of Directors Nov 14
Sotera Health Company Revises Earnings Guidance for the Year 2023 Nov 02
Third quarter 2023 earnings released: US$0.049 loss per share (vs US$0.089 profit in 3Q 2022) Nov 01
Sotera Health Company to Report Q3, 2023 Results on Nov 01, 2023 Oct 19
Sotera Health Company Revises Updated Earnings Guidance for the Full Year 2023 Aug 04
Second quarter 2023 earnings released: EPS: US$0.084 (vs US$0.11 in 2Q 2022) Aug 03
Now 21% undervalued after recent price drop Jul 10
Sotera Health Company Appoints Jon Lyons as Chief Financial Officer Jun 28 Sotera Health Company Appoints Jon Lyons as Chief Financial Officer
New minor risk - Share price stability Jun 25 Sotera Health Company Re-Affirms Revenue Guidance for the Year 2023
First quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 in 1Q 2022) May 03
Now 23% undervalued after recent price drop Apr 13
Now 21% undervalued Mar 23
Now 22% undervalued Mar 02
Full year 2022 earnings released: US$0.83 loss per share (vs US$0.41 profit in FY 2021) Mar 01
Sotera Health Company to Report Q4, 2022 Results on Feb 28, 2023 Feb 16
Sotera Health Company Reaffirms Earnings Guidance for the Year Ended December 31, 2022 Feb 14
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Sotera Health Company Jan 26
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Sotera Health Company Jan 25
Investor sentiment improved over the past week Jan 16
Sotera Health Company Announces Settlement of Ethylene Oxide Litigation in Illinois Jan 10
Investor sentiment improved over the past week Nov 25
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.09 (vs US$0.098 in 3Q 2021) Nov 03 Sotera Health Company Revises Earnings Guidance for the Full Year 2022
Sotera Health Company to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Sotera Health Company Announces Board Changes Oct 14
Investor sentiment deteriorated over the past week Sep 20
Sotera Health Company Announces Executive Changes, Effective October 1, 2022 Sep 07
Second quarter 2022 earnings released: EPS: US$0.11 (vs US$0.15 in 2Q 2021) Aug 05
Sotera Health Company Revises Earnings Guidance for the Full Year 2022 Aug 05 Sotera Health Company Announces Executive Changes
Investor sentiment improved over the past week Jun 07
Sotera Health Company Announces Departure of Scott Leffler as Chief Financial Officer, Effective August 12, 2022 May 20
First quarter 2022 earnings released: EPS: US$0.11 (vs US$0.038 in 1Q 2021) May 06
Sotera Health Company Reaffirms Earnings Guidance for the Year 2022 May 06
High number of new and inexperienced directors Apr 27
Sotera Health Company to Report Q1, 2022 Results on May 05, 2022 Apr 22
High number of new and inexperienced directors Apr 15
Sotera Health Company, Annual General Meeting, May 26, 2022 Apr 15
Sotera Health Company Announces Earning Guidance for Full Year 2022 Mar 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 02
Sotera Health Company to Report Q4, 2021 Results on Mar 01, 2022 Feb 10
Sotera Health Company Updates Revenue Guidance for the Full-Year 2021 Jan 12
President of Sterigenics recently sold €1.4m worth of stock Aug 29
Second quarter 2021 earnings released: EPS US$0.15 (vs US$0.03 in 2Q 2020) Aug 13
Sotera Health Company Reaffirms Earnings Guidance for the Year 2021 Aug 13 Sotera Health Company(NasdaqGS:SHC) dropped from Russell 3000E Value Index
First quarter 2021 earnings released: EPS US$0.039 (vs US$0.011 in 1Q 2020) May 14 Shareholder Returns SH5 DE Life Sciences DE Market 7D 3.3% 3.2% 3.0% 1Y -8.6% 4.8% 13.2%
See full shareholder returns
Return vs Market: SH5 underperformed the German Market which returned 13.1% over the past year.
Price Volatility Is SH5's price volatile compared to industry and market? SH5 volatility SH5 Average Weekly Movement 5.4% Life Sciences Industry Average Movement 7.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SH5 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SH5's weekly volatility (5%) has been stable over the past year.
About the Company Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Show more Sotera Health Company Fundamentals Summary How do Sotera Health's earnings and revenue compare to its market cap? SH5 fundamental statistics Market cap €3.53b Earnings (TTM ) €67.67m Revenue (TTM ) €1.08b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SH5 income statement (TTM ) Revenue US$1.12b Cost of Revenue US$502.46m Gross Profit US$618.01m Other Expenses US$547.52m Earnings US$70.49m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
Earnings per share (EPS) 0.25 Gross Margin 55.16% Net Profit Margin 6.29% Debt/Equity Ratio 473.4%
How did SH5 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 09:07 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sotera Health Company is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Polark Baird Luke Sergott Barclays Patrick Donnelly Citigroup Inc
Show 11 more analysts 